Geundoo Jang
About
Geundoo Jang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Geundoo Jang has authored 39 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Geundoo Jang's work include Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Geundoo Jang is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Viral-associated cancers and disorders (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Geundoo Jang collaborates with scholars based in South Korea, United States and Switzerland. Geundoo Jang's co-authors include Cheolwon Suh, Jooryung Huh, Shin Kim, Sung Sook Lee, Sora Baek, Kwonoh Park, Dok Hyun Yoon, Dae Ho Lee, Sun Jin Sym and Jae‐Cheol Jo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Advanced Energy Materials.
In The Last Decade
Geundoo Jang
35 papers receiving 391 citations
Peers
Geundoo Jang
Y.S. Chae South Korea
Motohiko Aiba Japan
Donna M. Weber United States
R. Biamonte Italy
Jean-François Emile France
L K Rajeev India
F Cavalli Switzerland
Zimu Gong United States
Robert S. Brody United States
Gene Resnick United States
Citations per year, relative to Geundoo Jang Geundoo Jang (= 1×)
peers
Y.S. Chae
Countries citing papers authored by Geundoo Jang
Since
Specialization
Citations
This map shows the geographic impact of Geundoo Jang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geundoo Jang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geundoo Jang more than expected).
Fields of papers citing papers by Geundoo Jang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Geundoo Jang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geundoo Jang. The network helps show where Geundoo Jang may publish in the future.
Co-authorship network of co-authors of Geundoo Jang
This figure shows the co-authorship network connecting the top 25 collaborators of Geundoo Jang. A scholar is included among the top collaborators of Geundoo Jang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geundoo Jang. Geundoo Jang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jang, Geundoo, et al.. (2025). Acute Care for Elders Risk Score: A Practical Machine Learning–Based Tool for Screening High-Risk Older Inpatients. Journal of the American Medical Directors Association. 26(10). 105818–105818.
2.
Jang, Geundoo, Jin Su Park, Jeongyeon Kim, et al.. (2025). A Push–Pull Type Electron-Selective Self-Assembled Monolayer in Organic Semiconductor Photoanodes for Solar Water Oxidation. ACS Energy Letters. 10(12). 6082–6091.
3.
Ferdowsi, Parnian, Geundoo Jang, Jin Su Park, et al.. (2025). Electron‐Selective Naphthalimide‐Based Monolayers for Tuned Energy Level Alignment in Halide Perovskite Solar Cells. Advanced Energy Materials. 15(48).
4.
Klempner, Samuel J., M. Beeram, Dhanusha Sabanathan, et al.. (2021). 209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. Annals of Oncology. 32. S450–S450.
5.
Han, Boram, Joo Young Jung, Hyeong Su Kim, et al.. (2016). A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer. Cancer Chemotherapy and Pharmacology. 78(5). 949–958.
6.
Yoon, Dok Hyun, Geundoo Jang, Jong Hoon Kim, et al.. (2015). Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics. 91(3). 489–496.
7.
Han, Boram, Choong Kee Park, Jong Hyeok Kim, et al.. (2013). Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 72(4). 845–852.
8.
Kwon, Jung Hye, Sung Yong Oh, Gary B. Chisholm, et al.. (2012). Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Supportive Care in Cancer. 21(4). 1175–1183.
9.
Kim, Jeong Eun, Dok Hyun Yoon, Geundoo Jang, et al.. (2012). A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. The Korean Journal of Hematology. 47(1). 53–53.
10.
Jang, Geundoo, Sung Sook Lee, Jin‐Hee Ahn, et al.. (2011). Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Research and Treatment. 128(1). 171–177.
11.
Jang, Geundoo, Kyun‐Seop Bae, Hei Sung Kim, et al.. (2011). Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. British Journal of Cancer. 104(4). 605–612.
12.
Kim, Hyeong Su, Gyeong‐Won Lee, Jung Han Kim, et al.. (2010). A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 70(1). 71–76.
13.
Kang, Byung Woog, Won Seog Kim, Chul Kim, et al.. (2009). Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Investigational New Drugs. 28(4). 516–522.
14.
Park, Inkeun, Jae‐Lyun Lee, Min‐Hee Ryu, et al.. (2009). Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 65(3). 473–480.
15.
Jo, Jae‐Cheol, Byung Woog Kang, Sun Jin Sym, et al.. (2009). Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Investigational New Drugs. 29(1). 175–181.
16.
Yoon, Dok Hyun, Byeong Seok Sohn, Geundoo Jang, et al.. (2009). Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non‐Hodgkin's lymphoma. Transfusion. 49(9). 1890–1900.
17.
Jang, Geundoo, et al.. (2008). Prospective randomized comparative observation of single‐ versus split‐dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non‐Hodgkin's lymphoma. Transfusion. 48(4). 640–646.
18.
Kim, Min Kyoung, Shin Kim, Geundoo Jang, et al.. (2007). A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collection. Journal of Clinical Apheresis. 22(5). 277–282.
19.
Jo, Jae‐Cheol, Geundoo Jang, Sun Jin Sym, et al.. (2007). BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Annals of Hematology. 87(1). 43–48.
20.
Kim, Eun‐Kyoung, Seung‐Jae Myung, Suk‐Kyun Yang, et al.. (2002). Cytomegalovirus Ileitis Manifested by Severe Bleeding in an Immunocompetent Individual. Korean Journal of Gastroenterology. 39(1). 59–63.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Y.S. Chae Breakdown of academic impact, for papers by Motohiko Aiba Breakdown of academic impact, for papers by Donna M. Weber Breakdown of academic impact, for papers by R. Biamonte Breakdown of academic impact, for papers by Jean-François Emile Breakdown of academic impact, for papers by L K Rajeev Breakdown of academic impact, for papers by F Cavalli Breakdown of academic impact, for papers by Zimu Gong Breakdown of academic impact, for papers by Robert S. Brody Breakdown of academic impact, for papers by Gene Resnick